Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055003 | 0.78 | HTT (0.52) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL22279019 | 0.78 | HTT (0.52) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL10055005 | 0.78 | MAPT (0.57) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL4943568 | 0.76 | MAPT (0.56) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL22278925 | 0.76 | ALDH1A1 (0.44) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL30339949 | 0.76 | ALDH1A1 (0.50) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL10062324 | 0.75 | POLB (0.46) | MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL7112667 | 0.75 | HIF1A (0.50) | MAPTALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL16680903 | 0.75 | MAPT (0.48) | MAPTALDH1A1MAOAMAOBKMT2A | |
| N-Benzylaniline SCHEMBL7840 | 0.74 | HTT (0.71) | ALDH1A1KMT2AMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | EMORY UNIVERSITY | 2016-01-07 | — | — | US | disclosed |
| US-20140248236-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY | 2014-09-04 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | MAPT 3864/4885ALDH1A1 3626/4885MAOA 399/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | MAPT 3864/4885ALDH1A1 3626/4885MAOA 399/4885 |
| US-20140248236-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | MAPT 3864/4885ALDH1A1 3626/4885MAOA 399/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | MAPT 4435/4885ALDH1A1 1269/4885MAOA 4550/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | MAPT 3864/4885ALDH1A1 3626/4885MAOA 399/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | MAPT 3864/4885ALDH1A1 3626/4885MAOA 399/4885 |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | CXCR4, CXCL12, CXCR1 | MAPT 4435/4885ALDH1A1 1269/4885MAOA 4550/4885 |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | CXCR4, CXCL12, CXCR1 | MAPT 4435/4885ALDH1A1 1269/4885MAOA 4550/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | MAPT 3864/4885ALDH1A1 3626/4885MAOA 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.